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ABSTRACT
Purpose To study the biorelevant drug release from novel
starch-based polyvinyl alcohol capsules (S-PVA-C). The effect of
the shell material is studied by considering microstructural formu-
lation changes during hydration.
Methods Two different self-emulsifying systems containing either
fenofibrate or probucol were filled in S-PVA-C, as well as capsules
of gelatin (SGC) and starch (VegaGels®). Release analysis
employed a BioDis® apparatus, while disintegration was studied
by texture analysis. For microstructural analysis we used small
angle x-ray scattering (SAXS).
Results S-PVA-C opened only partially in biorelevant media
compared to completely opened SGC and VegaGels®. In case
of the fenofibrate formulation, this opening mechanism caused
only a short lag time, while the probucol formulation in S-PVA-C
resulted in a sustained release. The latter formulation demon-
strated much higher viscosity upon hydration compared to the
fenofibrate system. Such a rheological effect on drug release was
barely noted for SGC or VegaGels® and SAXS revealed differ-
ences in the hydrated microstructure.
Conclusions Even though S-PVA-C are highly attractive for en-
capsulation of rather hydrophilic formulations, some care is need-
ed regarding an immediate release form. The type of formulation
hydration must be considered for adequate selection of the
capsule material.
KEY WORDS biorelevant release . controlled hydration .
disintegration . lipid-based formulation . thermoplastic capsule
INTRODUCTION
There has been a great interest in finding gelatin substitutes
for soft capsules in the last decade. This is due to known
gelatin drawbacks, for example animal sources, potential is-
sues of cross-linking, drug migration, or high water exchange
during drying between a hydrophilic fill mass and the gelatin
shell (1). Recently, we introduced (thermoplastic) starch-based
polyvinyl alcohol capsules (S-PVA-C) in pharmaceutics (2).
This soft capsule technology appeared to be especially prom-
ising for encapsulation of rather hydrophilic lipid-based sys-
tems. A typical problem of many self-microemulsifying or
nano-emulsifying drug delivery systems is that the presence
of hydrophilic formulation components can lead to issues of
capsule compatibility when gelatin is used as shell forming
material. The problem might be alleviated by addition of
excipients to the soft gelatin shell, but a more versatile alter-
native is to employ the novel S-PVA-C technology. This
thermoplastic capsule material was found to be suitable for
rotary die encapsulation and the previous study demonstrated
adequate drug release in a quality-control (QC) drug release
test (2).
Compendial drug release methods are used either in QC
testing or to predict in vivo drug release with regards to the
absorption process. Depending on the focus, the appropriate
dissolution media and conditions need to be selected. For
example, simplified aqueous media are typically used for rou-
tine QC purposes and more complex media might be required
for predicting in vivo absorption (3). Such more complex media
are especially needed for lipid-based formulations. The presence
of bile salts and phospholipids, as natural surfactants, has a
special importance in these drug release media. Due to their
amphiphilic nature, there can be an effect on drug solubiliza-
tion as well as on reduction of interfacial oil tension, which
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would affect formulation dispersion. To better simulate the
environment of gastro-intestinal (GI) fluids, many biorelevant
dissolution media have been developed and tested over the
last decade (4). Moreover, standard dissolution methodology
(paddles or baskets) may not adequately mimic the hydrody-
namics occurring in the GI tract, which was one of the reasons
to develop the reciprocal cylinder, i.e. USP apparatus 3
(BioDis®). Although it is themost attractivemethod for testing
extended-release products, some immediate release products
were also successfully analyzed (5). It seems to be attractive for
in vivo absorption prediction to combine the use of a USP
apparatus 3 with selecting biorelevant media. This is espe-
cially the case for poorly soluble, lipophilic drugs as demon-
strated by Jantratid et al. (6,7). One could argue that the most
physiological for lipid-based systems is to test in vitro lipolysis
(8,9). Such tests are advantageous with formulations that are
extensively digested. However, there is currently no standard-
ized vessel defined for lipolysis testing so that hydrodynamics
may differ from one equipment to another. Another drawback
compared to compendial testing is that the final dosage form
cannot be assessed with current lipolysis assays. Since we
focused rather on the effect of the shell material on drug
release, we selected biorelevant media in a USP apparatus 3.
In the last decade self-emulsifying lipid-based systems have
attracted increasing interest among scientists. These systems are
dosed as pre-concentrates in a capsule and upon administration
they disperse to microemulsions with a large surface area. The
process of self-emulsification is a complex and still debated
topic. Excellent reviews on the mechanisms of spontaneous
emulsification were written by Lopez-Montilla et al. and others
(10–13). Three principal mechanisms have been proposed for
spontaneous emulsification. A first mechanism is based on in-
terfacial turbulence, while another is called “diffusion and
stranding” and finally, the transient occurrence of a negative
interfacial tension has been discussed. It is also possible that
combinations of these principal mechanisms dominate the
aqueous dispersion of a self-emulsifying formulation.
The aqueous dilution of a pre-concentrate can possibly
exhibit a phase separation along the dilution line. Interesting
is the work of Regev et al. (14) who demonstrated that even in
case of a resulting one-phase system, the aqueous dilution of
the pre-concentrate typically passes through liquid crystalline
structures and/or a bicontinuous microemulsion area. Only
recently, small angle x-ray scattering (SAXS) was used in
pharmaceutics to study the intermediate hydration phases of
self-emulsifying drug delivery systems (15–18).
In the present work, we addressed the need to study the
biorelevant drug release from S-PVA-C. Self-emulsifying sys-
tems were used as model formulations and results were com-
pared to the release from soft capsules made of gelatin and of a
thermoplastic starch (VegaGels®). A particular aim was to
evaluate the interaction of the shell material and the type of
formulation hydration by studying microstructural changes.
MATERIALS AND METHODS
Materials
Fenofibrate (Sigma-Aldrich Chemie GmbH, Buchs, Switzer-
land) and probucol (Euroasian Chemicals Pvt Ltd, Mumbai,
India) were selected as poorly water-soluble model drugs.
Medium-chain triglycerides (Miglyol® 812) were supplied by
Hänseler AG (Herisau, Switzerland), soybean oil refined from
Georges Walther AG (Pfäffikon, Switzerland) and Transcutol
HP (2-(2-ethoxyethoxy)ethanol) by Gattefosse (Lyon, France).
Imwitor®742 (mediumchain partial glyceride)was obtained from
SASOL (Witten, Germany) and macrogol-glycerolhydroxystearat
(Cremophor® RH 40) from BASF (Ludwigshafen, Germany).
Polyoxyethylene (80) sorbitan monooleate (Tween® 80) and ace-
tonitrile of high-pressure liquid chromatography (HPLC) grade
were purchased from Sigma-Aldrich Chemie GmbH (Buchs,
Switzerland).
For the preparation of the fasted state simulated gastric fluid
(FaSSGF) and the fasted state simulated intestinal fluid
(FaSSIF), we purchased sodium chloride and sodium hydroxide
from Sigma-Aldrich Chemie GmbH (Buchs, Switzerland), pep-
sin and maleic acid from Hänseler AG (Herisau, Switzerland),
sodium taurocholate from Prodotti chimici e alimentari S.p.A.
(Basaluzzo, Italy), phosphatidylcholine from Lipoid GmbH
(Ludwigshafen, Germany), and hydrochloric acid (1 N) and
sodium hydroxide (1 N) from Scharlab (Barcelona, Spain).
The air-filled and oil-filled capsules (Table I), used for the
release testing, and the disintegration testing, were produced
at the technical facility at Swiss Caps AG, (Kirchberg,
Switzerland).
Methods
Preparation and Hydration of the Formulations
Two different self-emulsifying systems consisting of Tween®
80, Transcutol HP,Miglyol® 812, Imwitor® 742 (45%: 15%:
20%: 20% w/w; TTMI) and Cremophor® RH 40,
Transcutol HP, Miglyol® 812 (60%: 25%: 15%w/w;
CrMTrans) were used as model formulations. Since lipid-
based systems are generally tailor-made for each drug sub-
stance, we also employed two different formulations for the
active substances, i.e. TTMI for fenofibrate and CrMTrans
for probucol. Both mixtures (TTMI and CrMTrans) were
compounded in glass vials (by weight) using an analytical
balance (Mettler Toledo AB204-S). A magnetic stirring was
employed at 40°C until a clear solution was obtained. We
carefully checked for the absence of residual particles follow-
ing the cooling at room temperature. The prepared formula-
tions were hydrated with deionized water at water levels in the
range of 5–90%w/w and stored for 24 h at room temperature
(RT) before analysis.
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Preparation of Drug-Containing Formulations
Solubility Studies. For the system of fenofibrate in TTMI as
well as probucol in CrMTrans, an excess amount of drug was
added. The mixtures were constantly stirred (750 rpm on a
magnetic stirrer) in glass vials at RT. To ensure that equilib-
rium was reached, the solubility was determined after 18 h,
24 h, and 72 h. The samples were then centrifuged at 13,362 g
for 20 min using a Centrifuge 5415 R (Eppendorf AG, Ham-
burg, Germany). Finally, the concentrations of the active
compounds in the supernatant were determined after diluting
the supernatant with acetonitrile (1:500 v/v) by HPLC
analyses.
Drug-containing formulations were prepared by adding
fenofibrate to a clear solution of TTMI (FF-TTMI), and
probucol to CrMTrans (Pro-CrMTrans), both in drug con-
centration of 60mg/mL.
Characterization
Particle Size Measurements. Particle size of the diluted self-
emulsifying systems was analyzed by means of dynamic laser
light scattering using a Zetasizer Nano ZS (Malvern,
Worcestershire, United Kingdom). For individual measure-
ments, an aliquot (100 μL) of each preconcentrate was
obtained from a calibrated automatic pipette Eppendorf Re-
search® plus (20–200 μL) and dispersed in 20 mL of water
using a glass vial. Both formulations were assessed for their
ease of self-emulsification and qualitatively described as
“good”, “moderate” or “poor” (15). The diluted samples were
measured in dynamic light backscattering (173° angle) and the
mean particle size (Z-average diameter) was calculated from
the volume size distribution. All experiments were repeated in
triplicates from fresh samples at RT.
Rheological Studies. The rheological properties of low-viscous
lipid-containing colloids can be difficult to measure. For ade-
quate measurements using a cone-plate rheometer, there must
be a uniform force transmission in the sample. A loss of grip
between the cone and the sample shear plane is a problem that
especially occurs at comparatively high shear forces. For the
measurements of the hydrated formulations, we therefore
employed a new mechanical chip-based (MEMS) capillary rhe-
ometer (mVROC™ RheoSence, San Ramon, CA, USA). m-
VROC™ (Viscometer-Rheometer-on-Chip) is a microfluidic
slit rheometer used for fast and accurate measurements of the
viscosity of microliter sample volume solutions. It measures the
viscosity from the pressure drop of a sample as it flows through a
rectangular slit. The glass syringe (Hamilton 1010 C SYR
10 mL or Hamilton 81260 SYR 500 μL, depending on the
viscosity of the sample) was loaded with sample and placed
inside of the thermal jacket (25±0.5°C). When the measure-
ment temperature was stable, the sample was pumped to flow (at
shear rate 200 s−1) through the flow channel of the chip. The
pressure drop was detected by a sensor (cell m-VROC A-10 or
D-10) and the viscosity was calculated using m-VROC Control
Software™. The viscosities of TTMI and CrMTrans were
measured for hydration levels of 5–90% w/w. Results were
based on experiments in triplicates.
Small Angle X-ray Scattering (SAXS) Studies. SAXS was mea-
sured using a Bruker NANOSTAR setup with an Incoatec
IμS-microfocus Cu-Kα anode (wavelength 1.54 Å) and a
Bruker VANTEC-2000 detector. The samples were mea-
sured in flame-sealed glass capillaries with a diameter of
1.5 mm and a wall thickness of 1 μm. The 2D detector images
were taken at ambient temperatures and were azimuthally
averaged to produce 1D intensity profiles.
Fitting. The SAXS data were fitted using a Teubner-Strey
model for microemulsions (17,19). The Teubner-Strey model
is based on the Landau theory for microemulsions, where the
order parameter is associated with the “water-to-oil ratio” (19).
This model predicts a single broad maximum and a q−4-de-
pendance towards higher q-values (higher scattering angles).
Within this model the scattering intensity has the following
form:
I qð Þ∝ 1
aþ c1q2 þ c2q4 ð1Þ
The obtained parameters a, c1 and c2 are used to calculate
the two characteristic length scales d and ξ.
Table I Characteristics of Different Capsule Types
Type of
capsule
Capsule shell material Method of
production
Fill massa
Soft gelatin
capsules
Bovine gelatin, glycerol, and water
47.4%: 17.1%: 35.5% (w/w)
Casting and
rotary die
methodb
Soybean
oil
VegaGels® Potato starch, glycerol, sorbitol,
carrageenan, and water 66%:
18%: 10% : 1% : 5% (w/w)
Extrusion and
rotary die
methodc
Soybean
oil
S-PVA-Cd Potato starch, PVA, plasticizers
(sorbitol solution and glycerol)
40% : 30% : 30% (w/w)
Extrusion and
rotary die
methodb
Miglyol®
812
a Fill mass for those capsules used for the texture analysis of dosage form
disintegration
bMethods of production are described in Misic et al. (2)
c Method of production of VegaGels® is the same as for S-PVA-C
d S-PVA-C: starch-based polyvinyl alcohol thermoplastic capsules
196 Misic et al.
d ¼ 2π 1
2
a
c2
 1
2
−
1
4
c1
c2
" #−12
ð2Þ
ξ ¼ 1
2
a
c2
 1
2
þ 1
4
c1
c2
" #−12
ð3Þ
Here, d is the domain size (or periodicity) whereas ξ is
the correlation length, both together providing an indication
of the order in the system. The ratio ξ/d is a measure of the
correlation length in units of the periodicity.
Biorelevant Drug Release Studies. Drug release was studied
using the BioDis® apparatus (RRT 8, CALEVA Ltd, Dorset,
England) at 37±0.5°C using 220 mL of test medium in each
vessel, mesh sizes of 420 μm for both the top and bottommesh
of the glass cylinders and a dip rate of 10 dpm or 30 dpm,
respectively (20,21). Prior to each experiment, the air-filled
capsules were weighed before and after manual filling with
FF-TTMI or Pro-CrMTrans, to obtain an exact fill mass in
each capsule. The experimental set-up in this study was
supposed to mimic the fasted gastrointestinal tract (GIT).
Therefore we used FaSSGF (30 min) followed by FaSSIF
(60 min), prepared as described by Jantratid et al. (22).
At predetermined time points, a 2 mL sample was taken by a
syringe, immediately filtered through a 0.45 μm Nylon filter
(Titan 2 Syringe Filter, SUN SRi, Rockwood, TN, USA) and
analyzed by HPLC. The removed volume was replaced each
time with 2 mL of fresh medium. All experiments were
performed in triplicates.
Texture Analysis of Dosage Form Disintegration. A texture ana-
lyzer (TAXT2i; Stable Micro Systems, Surrey, United King-
dom) was assembled with a disintegration rig (originally de-
veloped for fast-melting tablets) to study the disintegration of
capsules. This mechanical test mimics the gastric disintegra-
tion conditions, while constantly maintaining the force and
measuring the distance as the sample disintegrates. The ap-
paratus was equipped with a 5 kg load cell and fitted with a
20 mm diameter cylindrical probe. The capsule was attached
with a strip of 3 mm wide double-sided tape to the underside
flat region of the probe end. Each capsule type was filled with
oil at the technical facility of Swiss Caps AG, (Kirchberg,
Switzerland) (Table I) and was analyzed in triplicates. A
double-jacketed glass vessel was connected with tubes to a
thermostat system to keep the disintegration medium
(FaSSGF, 100 mL) at 37±0.5°C. On the bottom of the
double-jacketed glass vessel was a (30 mm diameter) platform,
which was perforated to allow ingress of water beneath the
capsule. The speed of the probe with an attached capsule was
initially 2.0 mm/s until the surface of perforated platform was
detected at the force of 0.029 N (threshold value for triggering
the onset of texture analysis). Subsequently, the force of the
probe was 0.098 N with a speed of 3.0 mm/s and the distance
was measured to obtain a capsule disintegration profile. The
time of analysis was 30 min (consistent with 2.2.3.4. Biorelevant
drug release studies). All capsules were produced either on
pilot- (S-PVA-C) or on a production-scale (SGC, VegaGels®)
using rotary die filling machines at the Swiss Caps facility in
Kirchberg, Switzerland (Table I).
HPLCMethod. The drug content of each sample was determined
by HPLC (Agilent Technologies 1200 Series) using a degasser
(G1379 B), an isocratic pump (G1310A), an autosampler
(G1329A), a variable wavelength detector (G1314B), and a
LiChrospher 60, RP select B 125–4 (5 μm) column (Merck,
Darmstadt, Germany) at a flow rate of 1 mL/min. The HPLC
conditions are described in Table II.
RESULTS
Characterization
Particle Size Measurements
The self-emulsifying systems (CrMTrans and TTMI) used in
our study showed different spontaneous dispersion behavior in
water (ratio 1:200 v/v) at room temperature. We checked
each of the evolving dispersions visually and qualitatively
classified the ease of their self-emulsification as “good”, “mod-
erate” or “poor”. Since TTMI spontaneously formed a trans-
parent dispersion, it was categorized as “good” emulsifying
system. This ease of spontaneous self-emulsification behavior
was already described by Groves and Pouton (23,24). In
contrast, the formulation CrMTrans was rated as rather
“poor” emulsifier, since it formed flakes upon gentle agitation,
while following short vigorous stirring, the mixture became
completely transparent. This result was obviously caused by
the formation of viscous structures, which required higher
shear forces to disperse the system. Despite the differences in
their ease of self-emulsification, both systems resulted in
nanodroplets. The droplet sizes of CrMTrans and TTMI
Table II Overview of HPLC Methods Used for Active Compounds
Quantification
Active
compound
Mobile phase Injection
volume
UV
detection
Fenofibrate Acetonitrile : ammoniumacetate buffer
(pH 3.5; 25 mM) (65:35, v/v)
20 μL 287 nm
Probucol Acetonitrile : water (90:10, v/v) 10 μL 241 nm
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were found to be 23.0±1.6 nm (PDI=0.15) and 17.9±1.7 nm
(PDI=0.07), respectively. A statistically significant difference be-
tween the droplet sizes of diluted formulations was confirmed
with p<0.01 (t-test following an F-test that demonstrated the
homogeneity of sample variances).
Rheological Studies
Figure 1 shows differences in viscosities of the hydrated self-
emulsifying systems (TTMI and CrMTrans). We observed
that, in the case of CrMTrans, the viscosity at lower water
contents (10–25% w/w) increased with dilution. It may be
related to the swelling of the amphiphilic film as part of the
generated microstructure. This increase in viscosity, caused by
instantaneous formation of a transparent gel upon hydration,
was already visually observed during sample preparation.
With further increase in water volume fraction, continuous
hydration of the structure was observed. There was a sharp
increase in viscosity observed with the CrMTrans system
demonstrating a maximum at 30% w/w water, followed by a
decrease with further hydration. In contrast, TTMI exhibited
only a slight increase in viscosity at the hydration levels of
40%–50% (w/w).
Small Angle X-ray Scattering (SAXS)
SAXS was used to study microstructural changes in hydrated
formulations over the whole hydration range. We did not
expect a marked effect of the compounds on hydration, be-
cause both drugs are neutral, highly lipophilic and low concen-
trated. Therefore, the controlled hydration was studied using
placebo formulations. The peak positions of hydrated TTMI
shifted to smaller q-values with increasing water content and
became narrower up to 55% water content (Fig. 2). For the
hydrated CrMTrans, with the increasing water content from
10 to 25%, a shift of the peak to lower q-values and a
narrowing of the peak could be observed. The narrowest peak
was obtained at a water content of 30%. Further water increase
resulted in only slight shifts of the peak positions, while a
broadening of the peak with increasing water content was
noted. Both formulations exhibited at higher hydration levels
(for TTMI from 60% up to 90% and for CrMTrans from 35%
to 70%) an additional change in SAXS intensity for smaller q-
values (0.01–0.02 Å−1). The appearance of an additional
SAXS signal can be attributed to a coexistence of an
additional colloidal phase with the general microemulsion
structure.
The calculated domain sizes d and correlation lengths ξ
are shown in Figs. 3 and 4. For CrMTrans hydrated from
15% to 25%w/w, and from 45% up to 60%w/w an increase
in d was found, which was followed by a slight decrease for
water contents up to 90%. In contrast, a strong (linear) in-
crease of the correlation length ξ with increasing water
content from 10% to 30% w/w could be seen. After reaching
a maximum in ξ at 30% water content (ξ ≈ 190 Å), ξ sharply
decreased between 30% and 65% w/w with a subsequent
slower decrease towards higher water contents. Both the cal-
culated domain size d and the correlation length ξ of
hydrated TTMI demonstrated a linear increase with rising
water content up to 50% w/w, followed by slight decrease at
higher water contents. The exception was at 65% w/w hy-
dration level when d showed some increase compared to
other hydration levels.
Both formulations exhibited a maximum value in d as
well as with respect to the correlation length ξ. This
scattering behavior was reflecting a hydration process that
induced the formation of a more ordered phase. Following the
maximum domain size and correlation length, a reverse trend
in the swelling process started, which can be viewed as a phase
transition. Thus, dominance of a bicontinuous microemulsion
structure (with possible existence of local lamellar structures)
was receding to evolving colloids of a droplet type.
Analysis of Capsule Disintegration and Drug Release
To better characterize the mechanical changes of the shell
material, we used a capsule disintegration testing rig of texture
analysis. Thus, the capsule filled with oil (Table I) was placed
in biorelevant test medium (FaSSGF) at 37 ± 0.5°C and a
plate was kept at constant force to monitor changes in dis-
tance. Such changes of displacement were caused by the
specific hydration and capsule disintegration mechanisms
(Fig. 5). Both S-PVA-C and VegaGels® were first swelling
before rupture at the seam occurred. For S-PVA-C partial
opening at the seam was noticed by visual observation, where-
as for VegaGels® there was a fast and complete opening along
the seam. This difference in opening can also be seen in
their disintegration profiles. VegaGels® appeared to disinte-
grate in a two-steps process. A first stage corresponded to the
opening at the capsule seam, while the second stage was given
by the disintegration of the residual capsule halves. SGC
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Fig. 1 Viscosity profiles of the self-emulsifying systems upon hydration
measured at 200 s−1 and 25°C by m-VROC™ rheometer [CrMTrans (red
line), TTMI (blue line)]. The lines are presented as guides to the eye.
198 Misic et al.
exhibited a very fast and complete opening prior to dissolution
of the gelatin fragments.
The different disintegration behavior was also reflected by
the drug release profiles. Figure 6 depicts the release behavior
of fenofibrate formulation (FF-TTMI) in all three capsule
types using the biorelevant media. SGC and VegaGels®
showed an almost immediate drug release within the first
10 min, which was in agreement with the disintegration pro-
files confirming a complete capsule opening. A short lag time
was noted for the S-PVA-C, which was due to the partial
opening of these capsules.
Figure 7 presents the release behavior of the probucol
formulation (Pro-CrMTrans) in all three capsule types using
biorelevant media. The drug release of Pro-CrMTrans filled
in S-PVA-C in FaSSGF was incomplete with high variations
(10–30%). A subsequent change to FaSSIF exhibited sustained
and comparatively slow drug release also with high variability.
This observation may be attributed to the differences in vis-
cosity of Pro-CrMTrans compared to FF-TTMI. The drug
release of Pro-CrMTrans filled in SGC and VegaGels® was
complete after 30 min with a short delay.
To evaluate the effect of mechanical force on release be-
havior of the probucol formulation in S-PVA-C, we increased
the dipping rate from 10 dpm to 30 dpm. A rate of 10 dpm
provided an agitation that is generally considered as physio-
logical for dosage form release in the USP 3 (25). An increase
of the dip rate was therefore primarily of interest to mecha-
nistically study the probucol system. We targeted higher shear
forces caused by an increased agitation of the reciprocal
cylinder. However, the probucol formulation CrMTrans
barely revealed a difference in drug release when comparing
the two dip rates (Fig. 8).
DISCUSSION
For any new capsule technology it is important to study drug
release not only in standard buffer solutions but also using
Fig. 2 SAXS intensity profiles
(logarithmic scale) for
microemulsions consisting of (a)
TTMI and water and (b) CrMTrans
and water. The numbers next
to the each curve indicate different
water concentrations in the
mixtures. Each curve is shifted by
one order of magnitude with
respect to the previous one.
Fig. 3 Plot of domain size (periodicity) d versus hydration levels for both
model formulations (TTMI and CrMTrans). [CrMTrans (red line), TTMI (green
line)]. The lines are presented as guides to the eye to point at increase in
periodicity.
Fig. 4 Plot of correlation length ξ versus hydration levels for both model
formulations (TTMI and CrMTrans). The connecting lines are for the ease of
visualization.
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biorelevant media. Although these media only approximate
the composition of gastro-intestinal fluids, they still contain the
most important components, namely bile salts and phospho-
lipids, which facilitate solubilization of lipophilic drugs in
micelles. So the release of poorly soluble, lipophilic drugs is
usually enhanced compared to the release rate in simple
aqueous solutions (6).
In our previous work we focused on manufacturability and
general characterization of the novel thermoplastic soft cap-
sules (S-PVA-C). Benefits were shown for the encapsulation of
rather hydrophilic formulations and drug release was studied
in water only (2). Considering the importance of more phys-
iological drug dissolution, we focused in the present study on
biorelevant drug release using the USP apparatus 3. A special
aim was to better understand how the shell material affects
drug release by considering changes in the hydrated micro-
structure of selected self-emulsifying formulations.
Effect of the Shell Material
Disintegration in a compendial sense is defined as the state in
which any residue of the unit, except fragments of the capsule
shell, is a soft mass having no palpably firm core (26). The
process of disintegration consists theoretically of two steps:
opening of the capsules and the disintegration of the capsule
shell, which may overlap in time. In case of the gelatin cap-
sules, the opening process was usually fast (within the first
5 min) and seemed not to limit the drug release. In contrast
to gelatin, there was a general lack of knowledge about disin-
tegration of thermoplastic capsules or their drug release in
biorelevant media. This was not only true for the novel
material S-PVA-C but also for other thermoplastic capsules
such as VegaGels®. Since the thermoplastic capsules may
have a specific opening mechanism, depending on the nature
of the polymer, their disintegration profiles can vary. Both
VegaGels® and S-PVA-C are starch-based thermoplastic
capsules that are similar in their qualitative composition
(Table I). Their similarity was also reflected by the observed
disintegration profiles in biorelevant media. Texture analysis
of their disintegration process revealed a swelling (pre-disinte-
gration) before a rupture occurred at the seam of the capsules
(Fig. 5). Following an initial swelling, VegaGels® demonstrat-
ed a step-wise disintegration pattern. It was clearly possible to
distinguish a complete opening of the capsule from the disin-
tegration of the residual shell material. In contrast, S-PVA-C
first partially opened and then started to disintegrate, while
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Fig. 5 Comparison of disintegration profiles of oil-filled SGC, VegaGels®,
and S-PVA-C analyzed by texture analyzer in biorelevant medium (FaSSGF) at
37±0.5°C. Each curve is a single representative example of n=3
experiments.
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Fig. 6 Release behavior (n=3±SD) of fenofibrate formulation (FF-TTMI)
from S-PVA-C, SGC, and VegaGels® using the BioDis® apparatus in
biorelevant media at 37±0.5°C, 10 dpm (shaded part represents drug
release in FaSSGF, and non-shaded in FaSSIF).
Time (min)
D
ru
g 
r
el
ea
se
d 
(%
)
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
S-PVA-C
VegaGels®
SGC
Fig. 7 Release behavior (n=3±SD) of the probucol formulation (Pro-
CrMTrans) from S-PVA-C, SGC, and VegaGels® using the BioDis®
apparatus in biorelevant media at 37±0.5°C, 10 dpm (shaded part repre-
sents drug release in FaSSGF, and non-shaded in FaSSIF).
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Fig. 8 Effect of the mechanical force on release behavior of probucol
formulation (Pro-CrMTrans) in S-PVA-C in BioDis® apparatus in the
biorelevant media at 37±0.5°C (shaded part represents drug release in
FaSSGF, and non-shaded FaSSIF).
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they continued to open. This different opening pattern was
visually observed and was supported by the texture analytical
profiles. Moreover, this finding was in agreement with the
observed release profiles of S-PVA-C. In the case of the
fenofibrate formulation, a short lag time was noted, which
was attributed to the partial capsule opening. For the
probucol formulation, the interaction of the opening mecha-
nism and poor formulation dispersibility resulted in sustained
and comparatively slow drug release. Furthermore, there was
no influence noted of a varied hydrodynamics on the release
profile (Fig. 8). This was similar to the results of a previous
study in which a difference in typical dip rates of the USP
apparatus 3 barely affected drug release of tablets (27). A
complete and fast opening of SGC and VegaGels® assured
an immediate drug release, which was not depending on the
nature of the formulation with its hydration process.
In summary, the fenofibrate system easily self-emulsified
and drug release was therefore practically independent of the
used capsule shell. However, the model formulation of
probucol was critically depending on the type of capsule
opening. The partial opening of the S-PVA-C in combination
with the highly viscous hydrated formulation obviously
sustained the drug release. Such hindered drug diffusion was
not observed with the same formulation using the other tested
capsules that opened rapidly along their entire seam.
Effect of Microstructural Formulation Change
The results of the capsule opening as well as the drug release
testing showed, especially for S-PVA-C, that formulation
changes during water hydration can be critical. To better
understand such effects during self-emulsification, we studied
the preconcentrates at different hydration levels. The drug-
free formulations were studied while assuming that the com-
pounds would have a neglectable effect on hydration at the
rather low concentrations used in this study.
Both model formulations (CrMTrans and TTMI) exhibited
along the different hydration levels some similarities. Until the
viscosity maximum was reached, the system remained a clear
single phase. The drop of viscosity in both systems resulted in
slightly turbid mixtures that became practically transparent as
the water hydration levels increased. The probucol system
(CrMTrans) revealed a sharp increase in viscosity at an inter-
mediate hydration (10–25%, w/w), which was quite different
from the hydrated fenofibrate system (TTMI). Such a viscosity
peak was previously observed by Fanun (28) in hydrated
preconcentrates that were fully dilutable (as a single-phase). It
was assumed that structural transitions occurred from water-in-
oil to bicontinuous to oil-in-water microemulsions. This view of
structural transitions has also been reported by other authors
who studied similar self-emulsifying formulations (29). Howev-
er, the microstructural changes may still be specific for a given
system so that different rheological properties evolve during
hydration.
For the swelling of an amphiphile, the polar head group is
expected to play a key role. Both model systems comprised
rather hydrophilic surfactants with a substantial amount of
ethylene oxide units. However, the Cremophor-containing
formulation (CrMTrans) had a much higher surfactant con-
centration than the Tween-system (TTMI). This probably
contributed to the more viscous structures that were formed
upon water addition. Unfortunately, we could not compare
surfactant effects at the same concentration levels, because of
the individual phase behavior of the formulations that were
tailor-made for the different model drugs.
A better understanding of themicrostructure was targeted by
the analysis of SAXS data. Both systems demonstrated a typical
peak for the hydrated systems as it has been observed before in
hydrated microemulsion preconcentrates (16–18). Recently,
Patil et al. discussed the possibility that at least a part of such
structure was consisting of local lamellar structures (17). Such
structures can be viewed as small stacks of randomly oriented
lamellar structures. Local lamellar structures were initially re-
ported in microemulsions by Cabos et al. (30). Since there is a
lack of long-range and orientational order, no macroscopic
birefringence would be expected. Kogan et al. described the
existence of “ordered bicontinuous structures” as bicontinuous
microemulsions based on lamellar phases that have lost the long-
range order due to thermal distortions but kept the short-range
order (31). In our case, the SAXS diffractograms of both systems
developed comparatively ordered structures at an intermediate
hydration regime. This increase in ordering has been seen in a
shift of the peakmaxima to the lower angles (q) and a sharpening
of the peaks. The samples at intermediate hydration
levels were also examined by a polarized light microscope and
did not reveal any birefringence, which indicated that no
marked liquid crystalline structures were present. The
obtained structures were considered to be microemulsions
with some short-range order. For such intermediate hydration
levels, a bicontinuous microemulsions type is expected. Our
data showed in case of TTMI some linearity of d as a function
of different water amounts. More complex were changes in
the domain size of the CrMTrans system upon addition of
water. This formulation showed a maximum in ξ ≈ 190 Å at
30% w/w, whereas TTMI exhibited a strong linear
increase and reached its maximum only at ξ ≈ 110 Å at
55% w/w. It was a notable finding that the maximum in the
correlation length of the CrMTrans system corresponded to
the observed sharp viscosity peak. In contrast, hydrated
TTMI demonstrated neither a sharp peak in correlation
length nor in viscosity.
Our systems also exhibited a typical bell-shaped curve of ξ
as a function of the hydration level (Fig. 4). As earlier
reported by Fanun (18,28) this behavior could be correlated
with structural transitions. Another interesting property is the
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ratio of the correlation length to the domain size ξ/d, which
indicates a length of order that is relative to a typical domain
size. It has been argued that the product 2π times ξ/d might be
used to differentiate a bicontinuous microemulsion from anoth-
er type of a Windsor type IV system (14). However, some care is
needed with this theoretical argument because real Windsor
type IV systems can be difficult to assign to an ideal structural
type. Structures of different colloidal nature can also co-exist.
As explained earlier, it is well possible that stacks of local
lamellar structures were present in our model systems. Howev-
er, they could have been part of a bicontinuous microemulsion
at intermediate hydration levels.
A co-existence of different structures was also an interpre-
tation of the additional SAXS features at very low q, which
was observed at relatively higher water amounts in both
systems. This signal was likely due to larger colloidal structures
such as oil-swollen micelles. Hence, it may hold for the onset of
a transition to an oil in water microemulsion.
In summary, the SAXS data demonstrated clear differences
in the microstructures of the model systems in terms of how
the domain size d and the correlation length ξ changed
at different hydration levels. Interesting was the more complex
hydration process of the CrMTrans system, which was inferred
from the non-linearity of d as a function of increasing water
amounts. Our data suggested that different colloidal structures
can co-exist in hydrated self-emulsifying systems. The higher
structural ordering might have caused an increased viscosity.
Although, the microstructural analysis using SAXS effectively
complemented the rheological studies of the hydrated formula-
tions, it did not fully explain the huge differences in viscosity
between the two hydrated systems. More research is needed to
better understand how the microstructure of hydrated self-
emulsifying systems is affecting rheological properties.
CONCLUSIONS
This study focused on the biorelevant drug release from S-
PVA capsules. Texture analysis of capsule disintegration re-
vealed interesting findings. A clear difference was noted in the
mechanism of how the novel S-PVA capsules opened com-
pared to soft capsules of gelatin or of another thermoplastic
material (VegaGels®). The different opening mechanism was
relevant for the drug release depending on the given formu-
lation. We studied two model formulations which were both
preconcentrates of microemulsions, but they significantly dif-
fered in their hydrated microstructure. A better understand-
ing of these microstructures was achieved by SAXS analysis.
An interaction of the hydrated structures and the shell mate-
rial was identified for the drug release from the novel thermo-
plastic capsules.
Our results support the view that a capsule shell material
may not be freely selectable for a given formulation. While
initial formulation development is typically optimizing the
biopharmaceutical performance, some care is needed with
selecting an appropriate capsule technology. The choice of a
suitable shell material has to be based on improved knowledge
of formulation characteristics. Quality control failures in drug
release can be avoided by a better understanding of the mech-
anisms of capsule opening and the microstructural formulation
changes during hydration. Ultimately, such knowledge con-
tributes to designing quality into a capsule dosage form. This is
a step in the right direction towards the desired state of the
quality by design initiative as it is targeted by regulatory
authorities as well as by developers of drug products.
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